tiprankstipranks
Trending News
More News >
Arch Biopartners (TSE:ARCH)
:ARCH
Canadian Market

Arch Biopartners (ARCH) AI Stock Analysis

Compare
32 Followers

Top Page

TS

Arch Biopartners

(ARCH)

Rating:26Underperform
Price Target:
Arch Biopartners is currently facing significant financial distress with no revenue generation, large operational losses, and negative equity. These factors heavily weigh down its overall score. Technical indicators are mixed, showing some bearish signals but not overly negative. Valuation is also a concern, with a negative P/E ratio and no dividend yield. Strategic improvements are crucial for future stability and growth.

Arch Biopartners (ARCH) vs. iShares MSCI Canada ETF (EWC)

Arch Biopartners Business Overview & Revenue Model

Company DescriptionArch Biopartners (ARCH) is a biotechnology company focused on developing innovative solutions for medical applications. The company is engaged in the research and development of novel therapeutics that target inflammation, organ injury, and bacterial infections. Arch Biopartners is particularly known for its lead drug candidate, Metablok, which is aimed at treating complications arising from inflammation and organ injury in conditions such as sepsis, COVID-19, and other critical care indications.
How the Company Makes MoneyArch Biopartners primarily generates revenue through the development and commercialization of its drug candidates. The company invests in the research and development of its proprietary technologies, aiming to bring them to market either independently or through strategic partnerships with larger pharmaceutical companies. Revenue streams include potential licensing agreements, milestone payments, and royalties from successful commercialization of its drug candidates. Additionally, Arch Biopartners may receive government grants or research funding to support its development efforts, particularly for projects addressing unmet medical needs.

Arch Biopartners Financial Statement Overview

Summary
Arch Biopartners exhibits severe financial challenges across all primary financial statements. The absence of revenue, large operational losses, negative equity, and reliance on financing indicate a precarious financial position. Strategic interventions are needed to stabilize and improve financial health.
Income Statement
8
Very Negative
Arch Biopartners is facing significant challenges in its income statement. The company has reported zero revenue in the latest year, indicating a complete halt in sales or service income. Historical data shows a declining trend in revenue with consistent losses, as evidenced by negative EBIT and net income margins. The lack of profitability and revenue growth are major concerns.
Balance Sheet
15
Very Negative
The balance sheet reflects a highly leveraged position with negative stockholders' equity, signaling financial instability. The debt-to-equity ratio cannot be calculated due to negative equity, which poses a significant risk. Total liabilities surpass total assets, indicating insolvency. There is a negative equity ratio, highlighting financial distress.
Cash Flow
12
Very Negative
Arch Biopartners has negative free cash flow, reflecting insufficient cash generation from operations to cover capital expenditures and operating needs. With no operating cash flow and continuous negative free cash flow, the company is reliant on external financing, as seen in positive financing cash flows.
BreakdownTTMSep 2024Sep 2023Sep 2022Sep 2021Sep 2020
Income Statement
Total Revenue2.18M2.12M1.98M964.68K3.89M67.89K
Gross Profit-473.00K0.00-129.00K-503.00K-150.00K-2.12M
EBITDA-1.44M-3.53M-336.00K-101.00K-77.02K-4.45M
Net Income-2.45M-3.92M-3.33M-1.41M-1.17M-4.63M
Balance Sheet
Total Assets533.53K935.62K1.17M621.64K2.67M741.30K
Cash, Cash Equivalents and Short-Term Investments54.85K2.97K831.27K506.35K448.24K653.68K
Total Debt2.83M2.77M5.02M4.41M5.16M3.39M
Total Liabilities4.79M5.28M6.68M5.09M6.55M4.61M
Stockholders Equity-4.26M-4.35M-5.51M-4.47M-3.88M-3.87M
Cash Flow
Free Cash Flow-2.23M-2.33M-234.08K-1.08M-2.98M-1.90M
Operating Cash Flow-2.23M-2.33M-234.07K-1.08M-2.98M-1.90M
Investing Cash Flow0.000.000.000.000.000.00
Financing Cash Flow2.01M1.50M559.00K-421.37K2.78M2.16M

Arch Biopartners Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.78
Price Trends
50DMA
1.77
Negative
100DMA
1.80
Negative
200DMA
1.84
Negative
Market Momentum
MACD
<0.01
Positive
RSI
45.87
Neutral
STOCH
52.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ARCH, the sentiment is Negative. The current price of 1.78 is below the 20-day moving average (MA) of 1.82, above the 50-day MA of 1.77, and below the 200-day MA of 1.84, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 45.87 is Neutral, neither overbought nor oversold. The STOCH value of 52.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ARCH.

Arch Biopartners Peers Comparison

Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
¥342.56B10.47-2.86%2.57%11.81%-7.17%
TSFRX
58
Neutral
C$328.39M21.91%125.38%99.20%
53
Neutral
C$59.77M-97.22%-67.03%
45
Neutral
C$269.08M-108.05%
44
Neutral
$111.07M-64.18%-27.18%
TSONC
43
Neutral
$110.14M-211.24%0.10%
26
Underperform
C$125.60M90.17%-78.59%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:ARCH
Arch Biopartners
1.75
0.10
6.06%
TSE:ONC
Oncolytics Biotech
1.15
-0.26
-18.44%
TSE:MSCL
Satellos Bioscience
0.61
0.11
22.00%
TSE:FRX
Fennec Pharmaceuticals
12.16
4.22
53.15%
TSE:MDNA
Medicenna Therapeutics Corp
0.91
-1.03
-53.09%
TSE:EPRX
Eupraxia Pharmaceuticals
7.64
4.16
119.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 22, 2025